UI Heart and Vascular Center offers highly specialized, less-invasive heart therapies

Dr. Philip Polgreen and his collaborators received a five-year, $3.7M R01 grant from the National Institute of Allergy and Infectious Diseasesto support the upcoming project titled, “Estimating the risk for and severity of respiratory infections attributable to CFTR heterozygosity.”

Isabella Grumbach, MD, PhD, professor in Cardiovascular Medicine and Vice Chair for Research, was nominated and elected to the Association of University Cardiologists (AUC), a national organization for the country’s leaders in academic cardiology.

Led by Phillip Horwitz, MD, and James Rossen, MD, the UI Health Care Heart and Vascular team is the first in the state to perform a procedure called intravascular lithotripsy that uses sonic pressure waves to break up calcium build-up in heart arteries.

Opening any clinical trial requires the satisfaction of many regulatory requirements for very good reasons. Scores of people review applications, confer in committees, weigh risks and benefits, all to make sure that the investigator has patient safety as their guide.

Martha Carvour, MD, PhD, assistant professor in Infectious Diseases, will present her capstone project, “Optimizing Communication in Outpatient Parenteral Antimicrobial Therapy Amid the COVID-19 Pandemic,” at the 2021 American College of Physicians (ACP) Internal Medicine Meeting.

Shunguang Wei, PhD, assistant professor in Cardiovascular Medicine, received a four-year, $2.3M R01 grant from the NIH’s National Heart, Lung, and Blood Institute (NHLBI).

Thermogenic adipocytes are specialized cells capable of converting chemical energy into heat and regulating body temperature. However, aging and weight gain can deplete thermogenic adipocytes and increase insulin resistance.

Ryan Boudreau, PhD, associate professor in Cardiovascular Medicine, received a two-year $200,000 Innovative Project Award (IPA) from the American Heart Association.

A team of cystic fibrosis experts with University of Iowa Health Care has been awarded a five-year, $11.5 million grant by the National Heart, Lung, and Blood Institute to research molecular therapies for cystic fibrosis (CF) lung disease.